Cargando…
SLC31A1 Identifying a Novel Biomarker with Potential Prognostic and Immunotherapeutic Potential in Pan-Cancer
Solute carrier family 31 member 1 (SLC31A1) encodes a protein that functions as a homotrimer for the uptake of dietary copper. As a vital member of the cuproptosis gene family, it plays an essential role in both normal tissues and tumors. In this study, we analyzed SLC31A1 across human cancer types...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669416/ https://www.ncbi.nlm.nih.gov/pubmed/38001885 http://dx.doi.org/10.3390/biomedicines11112884 |
_version_ | 1785139691414093824 |
---|---|
author | Zhang, Pei Yang, Heqi Zhu, Kaiguo Chang, Chen Lv, Wanrui Li, Ruizhen Li, Xiaoying Ye, Tinghong Cao, Dan |
author_facet | Zhang, Pei Yang, Heqi Zhu, Kaiguo Chang, Chen Lv, Wanrui Li, Ruizhen Li, Xiaoying Ye, Tinghong Cao, Dan |
author_sort | Zhang, Pei |
collection | PubMed |
description | Solute carrier family 31 member 1 (SLC31A1) encodes a protein that functions as a homotrimer for the uptake of dietary copper. As a vital member of the cuproptosis gene family, it plays an essential role in both normal tissues and tumors. In this study, we analyzed SLC31A1 across human cancer types to gain a better understanding of SLC31A1’s role in cancer development. We searched for information using online databases to analyze, systematically and comprehensively, the role of SLC31A1 in tumors. Amongst nine cancer types, the expression of SLC31A1 was significantly different between tumors and normal tissues. According to further analysis, pancreatic cancer had the highest mutation rate of the SLC31A1 gene, and the methylation levels of the gene were significantly reduced in seven tumors. The expression of SLC31A1 is also linked to the infiltration of tumors by immune cells, the expression of immune checkpoint genes, and immunotherapy markers (TMB and MSI), suggesting that SLC31A1 may be of particular relevance in immunotherapy. This thorough analysis of SLC31A1 across different types of cancer gives us a clear and comprehensive insight into its role in causing cancer on a systemic level. |
format | Online Article Text |
id | pubmed-10669416 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106694162023-10-25 SLC31A1 Identifying a Novel Biomarker with Potential Prognostic and Immunotherapeutic Potential in Pan-Cancer Zhang, Pei Yang, Heqi Zhu, Kaiguo Chang, Chen Lv, Wanrui Li, Ruizhen Li, Xiaoying Ye, Tinghong Cao, Dan Biomedicines Article Solute carrier family 31 member 1 (SLC31A1) encodes a protein that functions as a homotrimer for the uptake of dietary copper. As a vital member of the cuproptosis gene family, it plays an essential role in both normal tissues and tumors. In this study, we analyzed SLC31A1 across human cancer types to gain a better understanding of SLC31A1’s role in cancer development. We searched for information using online databases to analyze, systematically and comprehensively, the role of SLC31A1 in tumors. Amongst nine cancer types, the expression of SLC31A1 was significantly different between tumors and normal tissues. According to further analysis, pancreatic cancer had the highest mutation rate of the SLC31A1 gene, and the methylation levels of the gene were significantly reduced in seven tumors. The expression of SLC31A1 is also linked to the infiltration of tumors by immune cells, the expression of immune checkpoint genes, and immunotherapy markers (TMB and MSI), suggesting that SLC31A1 may be of particular relevance in immunotherapy. This thorough analysis of SLC31A1 across different types of cancer gives us a clear and comprehensive insight into its role in causing cancer on a systemic level. MDPI 2023-10-25 /pmc/articles/PMC10669416/ /pubmed/38001885 http://dx.doi.org/10.3390/biomedicines11112884 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zhang, Pei Yang, Heqi Zhu, Kaiguo Chang, Chen Lv, Wanrui Li, Ruizhen Li, Xiaoying Ye, Tinghong Cao, Dan SLC31A1 Identifying a Novel Biomarker with Potential Prognostic and Immunotherapeutic Potential in Pan-Cancer |
title | SLC31A1 Identifying a Novel Biomarker with Potential Prognostic and Immunotherapeutic Potential in Pan-Cancer |
title_full | SLC31A1 Identifying a Novel Biomarker with Potential Prognostic and Immunotherapeutic Potential in Pan-Cancer |
title_fullStr | SLC31A1 Identifying a Novel Biomarker with Potential Prognostic and Immunotherapeutic Potential in Pan-Cancer |
title_full_unstemmed | SLC31A1 Identifying a Novel Biomarker with Potential Prognostic and Immunotherapeutic Potential in Pan-Cancer |
title_short | SLC31A1 Identifying a Novel Biomarker with Potential Prognostic and Immunotherapeutic Potential in Pan-Cancer |
title_sort | slc31a1 identifying a novel biomarker with potential prognostic and immunotherapeutic potential in pan-cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669416/ https://www.ncbi.nlm.nih.gov/pubmed/38001885 http://dx.doi.org/10.3390/biomedicines11112884 |
work_keys_str_mv | AT zhangpei slc31a1identifyinganovelbiomarkerwithpotentialprognosticandimmunotherapeuticpotentialinpancancer AT yangheqi slc31a1identifyinganovelbiomarkerwithpotentialprognosticandimmunotherapeuticpotentialinpancancer AT zhukaiguo slc31a1identifyinganovelbiomarkerwithpotentialprognosticandimmunotherapeuticpotentialinpancancer AT changchen slc31a1identifyinganovelbiomarkerwithpotentialprognosticandimmunotherapeuticpotentialinpancancer AT lvwanrui slc31a1identifyinganovelbiomarkerwithpotentialprognosticandimmunotherapeuticpotentialinpancancer AT liruizhen slc31a1identifyinganovelbiomarkerwithpotentialprognosticandimmunotherapeuticpotentialinpancancer AT lixiaoying slc31a1identifyinganovelbiomarkerwithpotentialprognosticandimmunotherapeuticpotentialinpancancer AT yetinghong slc31a1identifyinganovelbiomarkerwithpotentialprognosticandimmunotherapeuticpotentialinpancancer AT caodan slc31a1identifyinganovelbiomarkerwithpotentialprognosticandimmunotherapeuticpotentialinpancancer |